South Korea's LegoChem Biosciences Inc. has announced a license agreement with Elthera AG, a biotechnology sta...
South Korea based HanAll Biopharma is investing in Interon Laboratories, Inc., a US-based biotechnology company focusing...
A research team at Pohang University of Science and Technology (POSTECH) in South Korea has developed a smart conta...
SK bioscience, a South Korea-based innovative vaccine and biotech company committed to promoting human health from preve...
South Korean firm Wellmarker Bio (WMBIO) has entered a clinical trial collaboration and supply agreement with Merck (kno...
Synaffix B.V., a Dutch biotechnology company focused on commercialising its clinical-stage platform technology for the d...
Qurient, a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organisation ded...
South Korea-based startup Lunit, in partnership with leading precision oncology company Guardant Health in the US, has a...
Biotech startup SN BioScience and pharma major Boryeong have signed a domestic manufacturing technology transfer an...
At the 2023 J.P. Morgan Healthcare Conference in January, Samsung Biologics, a fully integrated CDMO offering state...
GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, has entered into a ...
The International Vaccine Institute (IVI), based in Seoul (South Korea) has launched an IVI Country Office in&...
Lotte Biologics CEO Richard Won-jik Lee has announced a blueprint to leap forward as a global contract development and m...
Genexine, a clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologi...
South Korea-based SK bioscience has announced that Richard Kensinger, PhD (Left), former Director and Head of Drug Subst...
South Korean diagnostics company NGeneBio Co. is accelerating its expansion into the ASEAN precision diagnosis market. ...
US-based Novavax, Inc. has announced that partner SK bioscience, based in South Korea, has received expanded manufacturi...
Since it is practically impossible to evaluate all interactions between new drug candidates and all marketed drugs durin...
